Clinical Trial Update: Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating guadecitabine plus pembrolizumab in recurrent ovarian, primary peritoneal, or fallopian tube cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Guadecitabine (guadecitabine)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Northwestern University | Conditions: Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2021-05-12